am 580 has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Wang, L | 1 |
DeMarco, SS | 1 |
Peaks, MS | 1 |
Maiorana-Boutilier, AL | 1 |
Chen, J | 1 |
Crouch, MJ | 1 |
Shewchuk, BM | 1 |
Shaikh, SR | 1 |
Phillips, CM | 1 |
Bridges, LC | 1 |
1 other study available for am 580 and Cutaneous T-Cell Lymphoma
Article | Year |
---|---|
RARĪ±/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Benzoates; Bexarotene; Cell Adhesion; Cel | 2017 |